{"a":[{"_":"Regeneron's Pasatru scores FDA approval in ultra-rare bone lesions disorder","$":{"href":"/pharma/regeneron-approval-fop","hreflang":"en"}}]}
RegulatoryapprovedPasatruPositive
AI Analysis
Summary
Regeneron's Pasatru has received FDA approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes soft tissues to turn to bone, becoming only the second approved treatment for this condition after over a decade of development.
Outcome Details
FDA approval for ultra-rare genetic condition FOP; second approved treatment
Importance:9/10
Sentiment:
0.90
FDA approvalultra-rare diseaseFOPRegeneron
Related Companies
Read the original article
Published by FiercePharma on August 18, 2026 10:14 AM